US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FUNDX FUTURE FUND OPPORTUNITIES ETF

28.27

+0.14040.50%

Post-market: 28.270.0010+0.00%16:10 EDT

Volume:15.39K

Turnover:435.55K

Market Cap:228.55M

PE:- -

High:28.33

Open:28.32

Low:28.25

Close:28.13

52wk High:31.30

52wk Low:25.44

Shares:8.09M

Float Shares:8.09M

Volume Ratio:1.24

T/O Rate:0.19%

Dividend:0.50

Dividend Rate:1.75%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Federal Reserve's diluted forward guidance fails to curb rate hike expectations, markets await July CPI for next rate path clues

What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation

Simply Wall St.

Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan

Bullion Rebounds Rely on Rate Path Evaluation

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

Halozyme price target raised to $105 from $93 at Morgan Stanley

Halozyme Therapeutics, Inc. : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $110 from $83

THOMSON REUTERS

Halozyme Therapeutics, Inc. : Wells Fargo Raises Target Price to $95 from $75

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)

Halozyme Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Halozyme Q2 FY26 GAAP Net Income Rises 39% to USD 229.9 Million; Revenue Increases 48% to USD 481 Million

Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84

Halozyme Therapeutics Outlook FY Adjusted EPS USD 8.65-9

THOMSON REUTERS

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Philadelphia Fed President Open to All Rate Path Options, Doesn't Rule Out Policy Tightening

Fed's Paulson Maintains Flexible Stance on Rates, Focusing on Underlying Inflation Trends

Guardant Health is Maintained at Overweight by Morgan Stanley

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/FFOX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FFOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","market":"US","secType":"STK","nameCN":"FUNDX FUTURE FUND OPPORTUNITIES ETF","latestPrice":28.269,"timestamp":1789675200000,"preClose":28.1286,"halted":0,"volume":15385,"hourTrading":{"tag":"盘后","latestPrice":28.27,"preClose":28.269,"latestTime":"16:10 EDT","volume":6,"amount":169.614,"timestamp":1789675804068,"change":0.001,"changeRate":0.000035,"amplitude":0},"delay":0,"changeRate":0.004991361105778447,"floatShares":8085000,"shares":8085000,"eps":0,"marketStatus":"Not Yet Opened","change":0.1404,"latestTime":"09-17 16:00:00 EDT","open":28.3201,"high":28.33,"low":28.25,"amount":435552,"amplitude":0.002844,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":28.1286,"sharesOutstanding":7155000,"nav":28.12,"aum":227350200,"dividendRate":0.017514,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.27,"preClose":28.269,"latestTime":"16:10 EDT","volume":6,"amount":169.614,"timestamp":1789675804068,"change":0.001,"changeRate":0.000035,"amplitude":0},"volumeRatio":1.240526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","floatShares":8085000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.240526,"shares":8085000,"dividePrice":0.4951,"high":28.33,"amplitude":0.002844,"preClose":28.1286,"low":28.25,"week52Low":25.44,"pbRate":"--","week52High":31.295,"institutionHeld":0,"latestPrice":28.269,"eps":0,"divideRate":0.017514,"volume":15385,"delay":0,"ttmEps":0,"open":28.3201,"prevYearClose":27.27,"prevWeekClose":28.55,"prevMonthClose":29.2799,"prevQuarterClose":30.29,"fiveDayClose":28.3455,"twentyDayClose":30.52,"sixtyDayClose":28.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FFOX\",params:#limit:5,,,undefined,":[{"date":"2025-12-31","symbol":"FFOX","amount":0.49447507,"announcedDate":"2025-12-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"FUNDX FUTURE FUND OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-02","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FFOX\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-31","recordDate":"2025-12-31","paymentDate":"2026-01-02","value":0.49447507,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FFOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FFOX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1186040777","title":"Federal Reserve's diluted forward guidance fails to curb rate hike expectations, markets await July CPI for next rate path clues","url":"https://stock-news.laohu8.com/highlight/detail?id=1186040777","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186040777?lang=en_us&edition=fundamental","pubTime":"2026-08-11 10:55","pubTimestamp":1786416951,"startTime":"0","endTime":"0","summary":"The Federal Reserve Chair Kevin Warsh is reshaping the central bank's communication strategy, softening traditional forward guidance and reducing explicit hints about future interest rate paths....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMOC","OOQB","DBND","MINT","US12M.BOND","XLRI","VCSH","DFLV","SPYI","TBT","JULD","UBmain","US2Y.BOND","VOO","HIBL","HMOP","EBUF","IEI","GOLY","SSO","WAMA","BOND","SGOV","SPYQ","JPST","US6M.BOND","BKLN","ESmain","KDRN","BUCK","MYCN","XLF","EVNT","SH","TMF","IVV","OEF","SCHO","SLWS","SMAX","VCIT","EDV","BK4534","MUB","SPXS","JFLX","KRX","QSWN","BK4588","KRE","NELS","BK4504","BSV","DMAX","SPUU","KBWB","TLH","HK0000934320.USD","AGZD","BBLB","TAXX","UDN","HYG","MUNX","AGG","TFJL","TIP","TXXI","VSHY","CIVG","LIAJ","SPXU","XTEN","ZROZ","TLT","VFH","VEXC","PBDC","UBT","SHY","US10Y.BOND","IEF","MFSB","SROI","EMPB","BCFN","USHY","IAT","BIL","FNK","BK4561","TLTW","MESmain",".SPX","UUP","GBIL","IBHJ","JUCY","LQD","SPYM","TLTI","VGSH","BK4585","SPDN","SPY","SPYB","DPST","LQID","PFLD","FLGV","NEMD","SPXL","IBCE","BWZ","BND","US3Y.BOND","TBIL","US5Y.BOND","OEX","TLTX","XBOX","CIK","IGOV","PAYH","BK4550","SPYU","US7Y.BOND","ISHG","KBE","SPYH","IBTJ","BWX","BBIB","FEM","EVG","BUYO","SCYB","FFOX","TNmain","TBJL","JAAA","FITZ","TSYW","FNCL","RAUS","SHV","BK4559","SKRE","XBIL","BIV","SECR","VGIT","MMAX","BK4581","ZTmain","THRV","TUA","TYO","ZBmain","VGLT","DVVY","NUAG","US30Y.BOND","BK4535","BOXX","SDS","CGUI","YSPY","NGHT","FAZ","GOVT","QMY","UPRO","BBSB","ZFmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963135","title":"What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963135","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658963135?lang=en_us&edition=fundamental","pubTime":"2026-08-11 08:40","pubTimestamp":1786408844,"startTime":"0","endTime":"0","summary":"Earnings, guidance and new deals put Halozyme Therapeutics in focus\nHalozyme Therapeutics (HALO) drew fresh attention after reporting second quarter revenue of US$481 million and net income of US$229.91 million, along with higher full year revenue guidance and new ENHANZE collaboration agreements.\nSee our latest analysis for Halozyme Therapeutics.\nThe latest earnings, higher 2026 revenue guidance and accelerated buybacks appear to have supported momentum in Halozyme Therapeutics, with a 30...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/what-halozyme-therapeutics-halo-guidance-raise-means-for-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/what-halozyme-therapeutics-halo-guidance-raise-means-for-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","FFOX","HALO","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658599689","title":"Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2658599689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658599689?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:13","pubTimestamp":1786392812,"startTime":"0","endTime":"0","summary":"Guardant Health grants 46,044 RSUs to 149 new employees under inducement planGuardant Health set inducement RSU grants covering 46,044 common shares for 149 new non-executive hires, with an Aug. 3, 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL208d3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","FFOX","GNOM","BK4535","GH","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","GDOC","PTH","LFSC","BK4551","BK4196","BK4588","HELX","GNMX","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114783192","title":"Bullion Rebounds Rely on Rate Path Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1114783192","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114783192?lang=en_us&edition=fundamental","pubTime":"2026-08-10 16:51","pubTimestamp":1786351884,"startTime":"0","endTime":"0","summary":"Following weaker-than-expected employment data on August 10, gold and silver rallied in tandem as declining yields and a softer US dollar eased short-term valuation pressures on precious metals. This...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFLV","IBCE","ZSL","FFOX","FITZ","SECR","MFSB","QMY","TXXI","JAAA","FNK","EVNT","JFLX","SROI","BKLN","KDRN","THRV","BK4585","BCFN","SLWS","GMOC","TAXX","CIK","SIVR","BK4588","EVG","CGUI","AGQ","SCYB","SLV","VSHY","PFLD","DVVY","BUYO","LQID","PAYH","NUAG","FNCL","IBHJ","BUCK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GHRS","FFOX","LU0109394709.USD","BK4007","GH","LFSC","BK4585","HELX","BK4588","GNMX","BK4551","BK4196","PSIL","GDOC","BK4539","LU0889565916.HKD","LU0320765992.SGD","GNOM","EKG","PTH","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LU0029864427.USD","LU0310800379.SGD","BK4588","BK4551","GSIB","LU0320765992.SGD","EKG","FFOX","PTH","HELX","PSIL","GNMX","LU0708994859.HKD","LU0128525929.USD","GDOC","LU0889565916.HKD","BK4207","BK4007","BK4535","LU1267930573.SGD","BK4585","BK4196","LFSC","GHRS","GNOM","GH","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","BK4539","BK4585","PTH","FFOX","XLV","LU0128526141.USD","THNR","GNMX","EKG","LFSC","LU0109394709.USD","XBI","INMD","BK4581","BK4082","BK4007","PSIL","LABU","IBRN","GDOC","LU0320765992.SGD","BK4196","BK4588","HCSG","LU0889565916.HKD","BK4139","GH","LU0029874061.USD","HELX","SRRK","GHRS","BK4551","BK4535","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649006","title":"Halozyme price target raised to $105 from $93 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649006?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:41","pubTimestamp":1786110082,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman raised the firm’s price target on Halozyme (HALO) to $105 from $93 and keeps an Overweight rating on the shares....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-105-from-93-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-105-from-93-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FFOX","LU0053671581.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610585","title":"Halozyme Therapeutics, Inc. : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $110 from $83","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610585?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:04","pubTimestamp":1786100654,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN44411S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0053671581.USD","FFOX","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657461763","title":"Halozyme Therapeutics, Inc. : Wells Fargo Raises Target Price to $95 from $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2657461763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657461763?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:46","pubTimestamp":1786099568,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nAZN4TCJNE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","HALO","BK4139","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364660","title":"Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364660?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:40","pubTimestamp":1786066808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Compass Therapeutics (CMPX) and Halozyme (HALO) with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-therapeutics-cmpx-and-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-therapeutics-cmpx-and-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","LABU","LU0029874061.USD","FFOX","BK4581","XBI","BK4137","BK4585","XLV","HALO","CMPX","LU0128526141.USD","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665956","title":"Halozyme Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665956","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665956?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:37","pubTimestamp":1786052254,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryHalozyme Therapeutics, Inc.HALO.OQreported quarterly adjusted earnings of $2.28 per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","FFOX","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657085","title":"Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657085?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047072,"startTime":"0","endTime":"0","summary":"Halozyme Q2 revenue jumps 48%, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany raised 2026 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","HELX","FFOX","LGND","BK4007","BK4139","LU0566484027.USD","RPRX","PBE","IHE","LU1559883803.SGD","LU0053671581.USD","IE0009354923.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657548","title":"Halozyme Q2 FY26 GAAP Net Income Rises 39% to USD 229.9 Million; Revenue Increases 48% to USD 481 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657548","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657548?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:04","pubTimestamp":1786046699,"startTime":"0","endTime":"0","summary":"Halozyme Q2 FY26 GAAP net income rises 39% to USD 229.9 million; revenue increases 48% to USD 481 millionHalozyme posted Q2 revenue up 48% year-over-year to USD 481 million, driven by royalty revenue ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL38QhQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","BK4139","HALO","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657765652","title":"Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2657765652","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657765652?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84Aug 06 (Reuters) - Halozyme Therapeutics Q2 operating income USD 287.7 million.Q2 net income USD 229.9 millionQ2 EPS USD 1.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXSR1CNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","LU0053671581.USD","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652090","title":"Halozyme Therapeutics Outlook FY Adjusted EPS USD 8.65-9","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652090?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXSR1CNH:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0053671581.USD","FFOX","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","BK4588","EKG","PTH","HELX","LFSC","GNOM","GNMX","LU0320765992.SGD","BK4585","LU0889565916.HKD","GH","LU0109394709.USD","GDOC","BK4196","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129270413","title":"Philadelphia Fed President Open to All Rate Path Options, Doesn't Rule Out Policy Tightening","url":"https://stock-news.laohu8.com/highlight/detail?id=1129270413","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129270413?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:10","pubTimestamp":1785856224,"startTime":"0","endTime":"0","summary":"The Philadelphia Fed President, Anna Paulson, who will have a vote on the Federal Open Market Committee (FOMC) in 2026, stated on Tuesday that she remains open to the future path of interest rates,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FNK","FFOX","SLWS","BK4585","BCFN","SCYB","SROI","TAXX","SECR","BKLN","EVG","CIK","THRV","TXXI","EVNT","JFLX","DFLV","GMOC","KDRN","LQID","VSHY","PFLD","IBHJ","BUYO","CGUI","JAAA","BUCK","FNCL","QMY","PAYH","DVVY","IBCE","MFSB","NUAG","FITZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199799752","title":"Fed's Paulson Maintains Flexible Stance on Rates, Focusing on Underlying Inflation Trends","url":"https://stock-news.laohu8.com/highlight/detail?id=1199799752","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199799752?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:01","pubTimestamp":1785848497,"startTime":"0","endTime":"0","summary":"Federal Reserve officials continue to show diverging views on the outlook for interest rates.Philadelphia Fed President Anna Paulson, a 2026 FOMC voter, stated Tuesday that she will keep an open mind...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JULD","LQID","GBIL","CGUS","VSHY","BK4588","SDS","XLF","PFLD","SPYQ","BSV","TLH","TLTW","SECR","RAUS","SROI","BK4534","SPDN","LSTB","VOO","BK4504","OEX","SH","FFOX","IAT","LIAJ","UPRO","BOND","TBIL","SPYI","EVNT","TMF","FLGV","ZTmain","FAZ","BIL","WAMA","TBT","USHY","KDRN","KBWB","SHY","BOXX","BK4561","ZROZ","CIVG","ESmain","HIBL","IEI","XBIL","SGOV","BWX","NEMD","US5Y.BOND","TFJL","BWZ","GOVT","BBIB","HK0000934320.USD","HYG","VGSH","SPY","TLT","VGIT","NUAG","US2Y.BOND","ZBmain","OEF","IBCE","SMAX","US3Y.BOND",".SPX","TYO","GMOC","BBSB","SPYH","BK4581","FNCL","OOQB","UBT","DPST","UUP","SPYB","TBJL","BUCK","TLTX","EBUF","VCIT","BBLB","FNK","AGG","SPXL","GOLY","SPUU","BKLN","BUYO","YSPY","ZFmain","MINT","IVV","BK4585","TIP","THRV","VGLT","JHCR","RIZE","SHV","DFLV","IGOV","XLRI","TSYW","JPST","VCSH","BND","SCYB","SLWS","TCPB","BK4535","KBE","EMPB","SCHO","TXXI","MYCN","CGUI","PBDC","SPYU","TLTI","NGHT","KRE","DVVY","PAYH","DBND","MFSB","TAXX","MUNX","MESmain","BCFN","JFLX","LQD","MUB","SPYM","VEXC","US6M.BOND","FEM","SSO","SKRE","UDN","NELS","MMAX","IBHJ","TNmain","US30Y.BOND","JAAA","BK4550","CIK","QMY","US7Y.BOND","VFH","FITZ","SPXU","DMAX","US10Y.BOND","BK4559","UBmain","EDV","US12M.BOND","ISHG","SPXS","KRX","IEF","EVG","HMOP","BOXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556059","title":"Guardant Health is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556059?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:44","pubTimestamp":1785847440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","FFOX","EKG","GDOC","GNOM","BK4551","BK4585","LFSC","BK4196","BK4535","GH","LU0109394709.USD","LU0889565916.HKD","GNMX","BK4588","HELX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":98,"code":"91000000","status":"200"}]}}